Cargando…
An academic hospital experience screening mRNA COVID-19 vaccine risk using patient allergy history
Autores principales: | Krantz, Matthew S., Stone, Cosby A., Rolando, Lori A., Nobis, Ana E., Koo, Grace, Corey, Kristen B., Bluestein, Sara B., Staso, Patrick J., Campbell, Emily M., Phillips, Elizabeth J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Academy of Allergy, Asthma & Immunology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8288228/ https://www.ncbi.nlm.nih.gov/pubmed/34293499 http://dx.doi.org/10.1016/j.jaip.2021.07.010 |
Ejemplares similares
-
Janssen COVID-19 vaccine tolerated in 10 patients with confirmed polyethylene glycol allergy
por: Bruusgaard-Mouritsen, Maria A., et al.
Publicado: (2022) -
A case of coronavirus disease 2019 messenger RNA vaccine tolerance and immune response despite presence of anti-polyethylene glycol antibodies
por: Corey, Kristen B., et al.
Publicado: (2022) -
Risk-stratified management to remove low-risk penicillin allergy labels in the patients with COVID-19 in the intensive care unit
por: Stollings, Joanna L., et al.
Publicado: (2023) -
Adverse Events and Safety of SARS-CoV-2 Vaccines: What’s New and What’s Next
por: Corey, Kristen B., et al.
Publicado: (2022) -
mRNA COVID-19 vaccine safety in patients with previous immediate hypersensitivity to pegaspargase
por: Koo, Grace, et al.
Publicado: (2022)